<DOC>
	<DOCNO>NCT02156375</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetic ( PK ) ( blood level ) comparability 2 different formulation ustekinumab , 90 milligram per milliliter ( mg/mL ) liquid vial ( LIV ) 5 mg/mL LIV , follow single intravenous administration 6 milligram per kilogram ( mg/kg ) ustekinumab , dilute saline , healthy participant .</brief_summary>
	<brief_title>A Pharmacokinetic Study Single-Dose Intravenous Ustekinumab Delivered 2 Different Liquid Vial Formulations</brief_title>
	<detailed_description>This multicenter ( one hospital medical school team work medical research study ) , randomize ( study drug assign chance ) , parallel ( clinical trial compare response two group participant receive different treatment ) , open-label ( people know identity intervention ) single-dose , inpatient/outpatient study healthy participant . The study consist follow period : Screening ( within 28 day study drug administration ) , inpatient period ( Day 1 4 ) outpatient period ( Day 141 ) . Eligible participant randomly assign 1:1 ratio either 1 2 treatment group ( , Ustekinumab 90 mg/mL Ustekinumab 5 mg/mL ) receive treatment Day 1 . The PK comparability 2 different formulation ustekinumab , diluted saline , evaluate primarily . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Have weight range 50.0 kilogram ( kg ) 90.0 kg , inclusive body mass index ( BMI ) 18.5 kilogram per square meter ( kg/m^2 ) 29.0 kg/m^2 , inclusive If woman , must incapable pregnancy use highly effective method birth control A woman must negative serum pregnancy test A man sexually active woman childbearing potential vasectomy must agree use barrier method birth control Participant must willing able adhere prohibition restriction specify protocol Are nonsmoker agree smoke 10 cigarette 2 cigar per day throughout study Participant currently history clinically significant medical illness medical disorder include malignancy Participant previously receive ustekinumab Participant know suspect intolerance hypersensitivity biologic medication include ustekinumab Participant receive investigational drug within specified period prior plan first dose study drug currently enrol investigational study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>STELARAÂ®</keyword>
</DOC>